Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...
Even as OpenAI works to harden its Atlas AI browser against cyberattacks, the company admits that prompt injections, a type of attack that manipulates AI agents to follow malicious instructions often ...
Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio amid competition among CD20xCD3 bispecific antibodies. The FDA has approved ...
Port fuel injection (PFI) was a major milestone in the early '80s. The integration of PFI rapidly changed the way fuel was delivered by increasing fuel economy and improving engine performance. Even ...
Add Yahoo as a preferred source to see more of our stories on Google. A general view during the opening of the plenary session of the 32nd session of the Ministerial Council of the Organization for ...
BISHKEK, Dec 1 (Reuters) - OSCE election observers said on Monday that a weekend parliamentary election in Kyrgyzstan had been efficiently run, but stifled by a restrictive campaign environment and ...
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium Subcutaneous amivantamab-lazertinib demonstrated noninferior ...
Cosentyx (secukinumab) comes as a subcutaneous injection under the skin or an intravenous (IV) infusion into a vein. Doctors may prescribe it to treat plaque psoriasis, psoriatic arthritis, and other ...
The FDA approved a subcutaneous formulation of the blockbuster cancer drug pembrolizumab (Keytruda Qlex) for use across the drug's numerous solid tumors indications. The new formulation combines ...
Compared with placebo, significantly greater proportions of patients treated with Tremfya achieved clinical remission and endoscopic improvement. HealthDay News — The US Food and Drug Administration ...
The FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.
Jelena Djukanovic denied charges of using her position in the Organisation for Security and Cooperation in Europe's mission to supply Serbia's intelligence agency, the BIA, with sensitive information.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results